Home > Haematology > ASH 2020 > Multiple Myeloma > Initial data of FcRH5/CD3 T-cell-engaging bispecific antibody

Initial data of FcRH5/CD3 T-cell-engaging bispecific antibody

Presented By
Dr Adam Cohen, University of Pennsylvania, Philadelphia, USA
Conference
ASH 2020
Trial
Phase 1, GO39775
Cevostamab is a humanised IgG-based T-cell-engaging bispecific antibody targeting both the most membrane-proximal domain of the Fc receptor-homolog 5 (FcRH5) on myeloma cells and CD3 on T cells. This dual binding facilitates efficient immunological synapse formation, resulting in T-cell activation and potent killing of myeloma cells [1]. Initial clinical activity and safety of cevostamab in relapsed/refractory multiple myeloma (R/R MM) were presented [2]. FcRH5 is a type I membrane protein expressed on B cells and plasma cells. FcRH5 is found on myeloma cells with near 100% prevalence, “making it an attractive target for myeloma immunotherapy,” Dr Adam Cohen (University of Pennsylvania, Philadelphia, USA) stated. GO39775 (NCT03275103) is an ongoing phase 1 trial evaluating the safety, activity, pharmacodynamics, and pharmacokinetics of cevostamab ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on